Clinical Outcome in Soft Tissue Sarcoma Patients with Lung Metastasis Who Received Metastasectomy and/or Radiofrequency Ablation: Tokai Musculoskeletal Oncology Consortium Study
- PMID: 34785953
- PMCID: PMC8590959
- DOI: 10.2147/CMAR.S333721
Clinical Outcome in Soft Tissue Sarcoma Patients with Lung Metastasis Who Received Metastasectomy and/or Radiofrequency Ablation: Tokai Musculoskeletal Oncology Consortium Study
Abstract
Purpose: Here, we investigated the oncological outcomes of lung metastasectomy and/or radiofrequency ablation (RFA) of 92 patients with soft tissue sarcoma (STS) at nine institutions.
Methods: The study cohort included 65 men and 27 women with a mean age of 59 years at the time of metastasis. The mean follow-up duration was 51 months. All patients underwent metastasectomy and/or RFA for lung metastasis.
Results: The mean maximum size of the initial lung metastasis was 14.6 mm. At the initial evaluation, 41 patients had a single metastasis, whereas 51 patients had multiple metastases. The mean number of metastasectomies and/or RFA was 2 per patient. A total of 70 patients underwent lung metastasectomy, whereas the other 13 underwent lung RFA. The remaining nine patients underwent both RFA and metastasectomy. The 5-year post-metastatic survival rate was 52%. The patients who underwent complete treatment for the initial metastasis had better post-metastatic survival rates than those who underwent incomplete treatment. A univariate analysis of all possible prognostic factors for complete treatment confirmed the predictive value of disease-free interval, metastasis at initial presentation, distribution, tumor size, and number of lung metastases. Of the 92 patients, 74 underwent complete treatment for initial metastasis; in these patients, univariate and multivariate analyses showed that a smaller tumor size and single-lung metastasis were prognostic factors for superior post-metastatic survival. The patients with a smaller (<11.5 mm) single metastasis had better post-metastasis survival. The 5-year post-metastatic survival rates were 89.9% for patients with a smaller (<11.5 mm) single metastasis versus 22.7% for patients with larger (>11.5 mm) and multiple metastases.
Discussion: We propose that complete treatment for lung metastasis in patients with STS may improve post-metastatic survival rates. Furthermore, tumor number and size are important variables for clinical decision-making.
Keywords: lung metastasis; metastasectomy; radiofrequency ablation; soft tissue sarcoma.
© 2021 Nakamura et al.
Conflict of interest statement
The authors declare no conflicts of interest for this study.
Figures



Similar articles
-
Impact of tumor volume doubling time on post-metastatic survival in bone or soft-tissue sarcoma patients treated with metastasectomy and/or radiofrequency ablation of the lung.Onco Targets Ther. 2017 Jan 31;10:559-564. doi: 10.2147/OTT.S121562. eCollection 2017. Onco Targets Ther. 2017. PMID: 28203089 Free PMC article.
-
Oncological outcome after lung metastasis in patients presenting with localized chondrosarcoma at extremities: Tokai Musculoskeletal Oncology Consortium study.Onco Targets Ther. 2016 Jul 29;9:4747-51. doi: 10.2147/OTT.S107638. eCollection 2016. Onco Targets Ther. 2016. PMID: 27536136 Free PMC article.
-
Prognostic influence of the treatment approach for pulmonary metastasis in patients with soft tissue sarcoma.Clin Exp Metastasis. 2020 Aug;37(4):509-517. doi: 10.1007/s10585-020-10038-y. Epub 2020 May 20. Clin Exp Metastasis. 2020. PMID: 32436018
-
Radiofrequency ablation as treatment for pulmonary metastasis of colorectal cancer.World J Gastroenterol. 2014 Jan 28;20(4):988-96. doi: 10.3748/wjg.v20.i4.988. World J Gastroenterol. 2014. PMID: 24574771 Free PMC article. Review.
-
Stereotactic Body Radiotherapy Versus Metastasectomy in Patients With Pulmonary Metastases From Soft Tissue Sarcoma.Clin Oncol (R Coll Radiol). 2020 May;32(5):303-315. doi: 10.1016/j.clon.2020.01.005. Epub 2020 Feb 2. Clin Oncol (R Coll Radiol). 2020. PMID: 32024603
Cited by
-
Is Lymphocyte C-Reactive Protein Ratio Useful for Predicting Survival in Patients with Non-Metastatic Soft Tissue Sarcoma?Cancers (Basel). 2022 Oct 24;14(21):5214. doi: 10.3390/cancers14215214. Cancers (Basel). 2022. PMID: 36358634 Free PMC article.
-
Up-to-date evidence on image-guided thermal ablation for metastatic lung tumors: a review.Jpn J Radiol. 2022 Oct;40(10):1024-1034. doi: 10.1007/s11604-022-01302-0. Epub 2022 Jul 2. Jpn J Radiol. 2022. PMID: 35778630 Free PMC article. Review.
-
The Role of Trabectedin in Soft Tissue Sarcoma.Front Pharmacol. 2022 Feb 23;13:777872. doi: 10.3389/fphar.2022.777872. eCollection 2022. Front Pharmacol. 2022. PMID: 35281940 Free PMC article. Review.
-
Special Issue: "Pediatric Orthopedic Malignancy: Types, Symptoms, and Treatment".Children (Basel). 2023 Sep 13;10(9):1545. doi: 10.3390/children10091545. Children (Basel). 2023. PMID: 37761506 Free PMC article.
-
C‑reactive protein and related predictors in soft tissue sarcoma (Review).Mol Clin Oncol. 2023 Nov 24;20(1):6. doi: 10.3892/mco.2023.2704. eCollection 2024 Jan. Mol Clin Oncol. 2023. PMID: 38125741 Free PMC article. Review.
References
-
- Nakamura T, Matsumine A, Takao M, et al. Impact of tumor volume doubling time on post-metastatic survival in bone and soft- tissue sarcoma patients treated with metastasectomy and/or radiofrequency ablation of the lung. Onco Targets Ther. 2017;10:559–564. doi:10.2147/OTT.S121562 - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources